分类： ACN Newswire

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，中国台湾地区药政主管部门（TFDA）已正式受理维长宁（艾曲莫德，中国台湾地区商品名："維長寧"）用于治疗中重度活动性溃疡性结肠炎（UC）患者的新药上市许可申请（NDA）。这一进展标志着艾曲莫德继在中国澳门、新加坡和中国香港获批以及韩国NDA获正式受理之后，在亚洲市场的准入取得又一重大里程碑。中国国家药品监督管理局也于2024年12月正式受理艾曲莫德（维适平(R)）的新药上市申请，预计将在今年年底或明年年初获批。艾曲莫德是一款针对溃疡性结肠炎，每日一次的口服一线治疗药物，能够强效实现肠道黏膜愈合，且使用便捷，并具有良好的安全性特征。黏膜愈合是国内外溃疡性结肠炎临床指南一致认定的溃疡性结肠炎治疗目标。溃疡性结肠炎患者尽早实现黏膜愈合，可大幅降低疾病复发率、住院率、结直肠切除手术率和结直肠癌发生风险。艾曲莫德已被纳入2024年美国胃肠病学协会（AGA）临床实践指南, 推荐作为溃疡性结肠炎的一线治疗。2025年，艾曲莫德获得2025年美国胃肠病学会（ACG）成人UC临床指南的一线治疗推荐，进一步印证了其全球专业共识下的临床价值。云顶新耀首席执行官罗永庆先生表示："此次在中国台湾地区NDA申请的正式受理，是维长宁亚洲商业化进程中的又一重要进展。随着亚洲地区溃疡性结肠炎患者人数持续增长，临床上存在巨大未满足需求。仅在中国，2024年溃疡性结肠炎患者数量约为80万人，预计到2030年将达100万人。患者面临长期治疗与生活质量的双重挑战。此次受理充分体现了对维长宁临床价值的高度认可。我们将继续加快这一创新疗法在中国大陆及亚洲其他市场的上市进程，提升可及性，帮助患者实现长期疾病控制并改善生活质量。"本次申请基于ELEVATE UC III期注册研究（ELEVATE UC 52和ELEVATE UC 12）和ENLIGHT研究（ES101002）的结果。ELEVATE UC III期注册研究显示，在既往常规治疗、生物制剂或JAK抑制剂治疗失败或不耐受的中重度活动性溃疡性结肠炎患者中，每日一次2mg艾曲莫德在第12周和第52周均显示卓越且持久的临床缓解和内镜下深度黏膜愈合，且安全性良好，与既往研究一致。同时，ENLIGHT研究作为迄今最大规模的亚洲中重度UC III期注册临床研究，在中国大陆、中国台湾及韩国开展，共纳入340名患者。研究结果显示，艾曲莫德在诱导期和维持期均取得了显著且具有统计学意义的疗效优势，为其在亚洲人群中的应用提供了有力证据支持。作为云顶新耀在自身免疫性疾病领域的重磅产品，艾曲莫德已于2024年被纳入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录，在大湾区先行使用，惠及UC患者，并成为公司第三款商业化新药。今年3月，云顶新耀已启动艾曲莫德在嘉善工厂的本地化生产建设项目，以支持其在大中华区及亚洲其他市场的供应与商业化落地。 Copyright 2025 亚太商讯 via SeaPRwire.com.

广州，2025年8月15日 - (亚太商讯 via SeaPRwire.com) - 近日，中国电子信息行业联合会公布最新一批获颁数据管理能力成熟度（简称"DCMM"）等级证书企业名单，广发证券获评最高等级五级（优化级）认证，成为行业首家获评最高等级的证券公司，标志着公司在数据管理和应用方面达到国内领先水平，为行业数据管理能力建设树立标杆。《数据管理能力成熟度评估模型》（GB/T 36073-2018）是我国数据管理领域正式发布的首个国家标准。该认证从数据战略、数据治理、数据架构、数据应用等多个维度，全面评估企业的数据管理能力。其中，五级（优化级）作为最高等级，标志着企业的数据管理已形成行业最佳实践，具备强大的示范引领作用。一直以来，广发证券高度重视数据管理能力的建设与提升，将数据视为企业核心资产。公司构建了"战略引领、全员参与、跨部门协同、全生命周期管理"的数据管理体系。通过制定清晰的数据战略规划，完善数据治理组织架构与制度流程，强化数据安全与合规管理，持续提升数据质量与应用效能，公司实现了数据管理从"规范"到"优化"的跨越式发展，为业务创新、客户服务升级及风险管理提供了强有力的数据支撑。广发证券副总经理、首席信息官辛治运表示："公司将以此次获得DCMM五级认证为新的起点，持续深化数据管理能力建设，进一步完善数据治理长效机制，推动数据技术与业务场景的深度融合，并以此为契机，不断提升服务实体经济的质效，为证券行业的数据管理创新与发展贡献更多力量。" Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

阿联酋拉斯海马市, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 阿勒哈伊马国际公司注册中心（RAK ICC）宣布对其2019年《基金会条例》进行重大修订，新规已于2025年7月31日生效。此次修订是该制度自推出以来最为重要的更新之一，进一步巩固了阿联酋作为财富架构与长期资产保护竞争性司法辖区的地位。RAK ICC基金会因其灵活性、保密性及法律稳健性而广受认可，成为阿联酋国内外高净值人士、企业家及家族办公室的首选架构工具。这类结构通常用于继承规划、家族治理，以及将多元化资产整合于单一法律实体之下。2025年的修订引入了更强的法律保障及改进的治理措施，包括：1. 防火墙条款 —— 对与RAK ICC法规相冲突的外国判决提供更强有力的保护。2. 三年诉讼时效 —— 将对基金会设立或资产转移提出异议的时限限制为三年。3. 诉因条款 —— 债权人欺诈索赔仅限于涉案的特定资产，且仅在该行为导致创办人资不抵债时才适用。4. 胁迫与高管保护 —— 宣告在外国法律胁迫下采取的行为无效，从而保障基金会内部治理的自主权。5. 强化仲裁机制 —— 允许通过具备法院级权力的私下仲裁方式解决争议。6. 私人受托基金会条款 —— 明确基金会作为受托人持有财产时的资产隔离及受信义务的完整性。在RAK ICC基金会持有的资产现将享有更强的防火墙保护，确保与阿联酋法律相冲突的外国判决无法对其执行。新规设立了三年的时效期，用于限制对基金会成立或资产转入的质疑，为创办人及受益人提供更大的确定性。改革还收紧了债权人保护规则，在欺诈性转让索赔中须证明创办人资不抵债，并将责任限定在争议资产的价值范围内，以防涉及无关财产。此外，修订后的法规着重维护治理完整性和运营韧性。基金会高管在收到与RAK ICC法律不一致的外国命令时，必须予以忽略，从而保障基金会决策的自主权。新框架明确规定，基金会作为受托人持有的信托财产在法律上独立且与基金会自有财产分离，确保资产隔离的清晰性。争议解决机制也得到了强化，扩大的仲裁条款赋予仲裁庭类似法院的权力，使争议能够高效、保密地解决，并符合国际最佳实践。这些变化是RAK ICC维护前瞻性法律与监管环境整体战略的一部分，旨在满足全球标准的同时兼顾客户群体的特定需求。这也体现了该司法辖区在支持兼顾控制、隐私与长期安全的高端财富规划策略方面的承诺。通过强化其基金会制度，RAK ICC正巩固其在阿联酋的地位，成为寻求安全、灵活且符合国际合规标准的财富保全与跨代规划解决方案的可信赖合作伙伴。关于RAK ICC阿勒哈伊马国际公司注册中心（Ras Al Khaimah International Corporate Centre，简称RAK ICC）是一家总部位于阿联酋阿勒哈伊马的公司注册机构。该机构提供国际商业公司及基金会架构，通常用于私人及商业结构设计、资产整合以及继承规划。截至目前，RAK ICC已注册成立数千家国际公司，并为数十亿迪拉姆的结构化资产提供支持。其服务对象包括高净值人士、企业家及寻求灵活、安全的长期商业与财富管理方案的企业。媒体咨询请联系我们:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/来源: RAK ICC Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 中国辣味休闲食品行业龙头企业，卫龙美味全球控股有限公司（"卫龙美味"或"集团"）及附属公司（"集团"）（ 香港联交所股票代码：09985）公布截至2025年6月30日止六个月（"期内"）之中期业绩。人民币截至6月30日止六个月2025年2024年变动收入34.83亿29.39亿+18.5%毛利16.42亿14.62亿+12.3%毛利率47.2%49.8%-2.6个百分点期内净利润7.36亿6.21亿+18.5%净利润率21.1%21.1%保持稳定中期股息0.18元/普通股0.16元/普通股+12.5%2025年上半年，在全球消费增长普遍承压下，中国消费市场依然是全球最大消费市场之一。 得益于中国休闲食品市场近年来呈现出稳健的增长态势，报告期内，卫龙美味紧跟行业发展趋势，坚持多品类产品策略，聚焦创新，深度开展消费者洞察，精准捕捉市场需求，持续强化研发实力，并持续以年轻人喜爱的方式深化品牌渗透，通过各种线上线下的品牌活动搭建多维消费场景链接深化品牌渗透，持续推进全渠道覆盖能力和销售网络，进而为客户及消费者提供更好的服务和体验。报告期内，卫龙美味经营策略成效彰显，业绩持续稳健攀升，收入与净利润均录得双位数增长。2025年上半年实现总收入34.83亿元（人民币，下同），同比增长18.5%，主要由于集团期内持续加强全渠道和品牌建设，并优化渠道结构。尽管报告期内部分原材料成本上涨导致集团毛利率由去年同期的49.8%下降2.6个百分点至47.2%，但在收入增长及集团积极提升供应链效率的共同因素驱动下，毛利仍同比增长12.3%至16.42亿元。同时受惠于集团经营利润的提升，集团期内净利润同比增长18.5%至7.36亿元；净利润率得以维持去年同期水平，为21.1%。基于期内整体绩效表现，集团董事会决议派发2025年中期股息每股人民币0.18元，派息比率约为60%，预计派付股息日期为2025年10月20日或前后。产品方面，集团坚持多品类产品策略，从新产品、新口味、新工艺、新包装等维度发力，如拓展风味创新边界，深度回应消费者对创新口味的需求。2025上半年，集团先后先后推出了麻酱口味"魔芋爽"以及麻辣牛肉口味"亲嘴烧"等多个新品，进一步拓展并丰富产品组合，提升产品品质，满足市场多元化及个性化的消费需求，驱动产品力与市场需求匹配。品牌建设方面，集团持续以年轻人喜爱的方式深化品牌渗透，透过各种线上线下的品牌活动搭建多维消费场景链接，譬如联合林里柠檬茶发起"爆辣挑战"，凭借爆款销量与话题效应触达更多消费者；携手国潮品牌哭喊中心推出"大儿童专属"系列，借节日营销勾起青春味觉记忆。此外，集团于报告期内官宣王安宇担任魔芋爽代言人，借力明星影响力拓宽传播路径。集团的一系列举措有效触达年轻客群，夯实了品牌年轻化与趣味化的发展根基。渠道方面，集团持续推进线下全渠道、线上全平台覆盖策略。随着各种新兴渠道业态的兴起，集团紧跟渠道变化，持续拓展终端网点，强化销售团队终端执行力，并联合经销商持续提升终端的服务能力和产品铺市率，从而有力推动线下终端业绩稳步增长。在线上领域，集团同样积极布局，构建全平台生态体系，确保与线下渠道形成有效联动，助力全渠道发展战略落地。此外，集团始终致力于生产设施的自动化升级与技术创新突破，同步加快各业务系统的数字化转型进程。在此基础上，集团不断强化组织发展与核心人才梯队建设，以此全面提升公司整体运营效能，为业务的持续稳健发展注入强劲动力。卫龙美味董事长刘卫平先生表示："集团将始终坚守"多品类"产品策略，坚持产品创新，持续加码品牌建设力度，不断强化卫龙"年轻、有趣、有创意"的品牌形象与独特调性。与此同时，集团积极拥抱变化，持续加强全渠道的覆盖能力，为消费者提供更便捷的消费体验。展望未来，集团将以更积极、更主动的心态拥抱市场的变化，以更好的产品、更优质的服务和体验不断提升我们的竞争力，持续为消费者、客户、员工、投资人及社会创造更大的价值。"关于卫龙美味全球控股有限公司卫龙美味全球控股有限公司（"卫龙美味"）是中国领先的集研发、生产及销售为一体的辣味休闲食品企业，拥有强劲的增长势头和颇具影响力的品牌。 卫龙美味以传统美食为基础开创了中国调味面制品（俗称辣条）行业，于2001年开创出第一根辣条，并引领了辣条行业标准建设。 凭借出众的品类拓展能力，本集团已成功扩展至蔬菜制品、豆制品及其它产品等品类，推出了包括魔芋爽、风吃海带、小魔女等大单品。 卫龙美味是倍受中国年轻消费者喜爱的休闲食品品牌，拥有有效触达年轻消费者的全渠道销售及经销网络。 如欲获得更多信息，请浏览： https：//www.weilongshipin.com/。 Copyright 2025 亚太商讯 via SeaPRwire.com.

阿联酋拉斯海马市, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - 阿勒哈伊马国际公司注册中心（RAK ICC）宣布对其2019年《基金会条例》进行重大修订，新规已于2025年7月31日生效。此次修订是该制度自推出以来最为重要的更新之一，进一步巩固了阿联酋作为财富架构与长期资产保护竞争性司法辖区的地位。RAK ICC基金会因其灵活性、保密性及法律稳健性而广受认可，成为阿联酋国内外高净值人士、企业家及家族办公室的首选架构工具。这类结构通常用于继承规划、家族治理，以及将多元化资产整合于单一法律实体之下。2025年的修订引入了更强的法律保障及改进的治理措施，包括：1. 防火墙条款 —— 对与RAK ICC法规相冲突的外国判决提供更强有力的保护。2. 三年诉讼时效 —— 将对基金会设立或资产转移提出异议的时限限制为三年。3. 诉因条款 —— 债权人欺诈索赔仅限于涉案的特定资产，且仅在该行为导致创办人资不抵债时才适用。4. 胁迫与高管保护 —— 宣告在外国法律胁迫下采取的行为无效，从而保障基金会内部治理的自主权。5. 强化仲裁机制 —— 允许通过具备法院级权力的私下仲裁方式解决争议。6. 私人受托基金会条款 —— 明确基金会作为受托人持有财产时的资产隔离及受信义务的完整性。在RAK ICC基金会持有的资产现将享有更强的防火墙保护，确保与阿联酋法律相冲突的外国判决无法对其执行。新规设立了三年的时效期，用于限制对基金会成立或资产转入的质疑，为创办人及受益人提供更大的确定性。改革还收紧了债权人保护规则，在欺诈性转让索赔中须证明创办人资不抵债，并将责任限定在争议资产的价值范围内，以防涉及无关财产。此外，修订后的法规着重维护治理完整性和运营韧性。基金会高管在收到与RAK ICC法律不一致的外国命令时，必须予以忽略，从而保障基金会决策的自主权。新框架明确规定，基金会作为受托人持有的信托财产在法律上独立且与基金会自有财产分离，确保资产隔离的清晰性。争议解决机制也得到了强化，扩大的仲裁条款赋予仲裁庭类似法院的权力，使争议能够高效、保密地解决，并符合国际最佳实践。这些变化是RAK ICC维护前瞻性法律与监管环境整体战略的一部分，旨在满足全球标准的同时兼顾客户群体的特定需求。这也体现了该司法辖区在支持兼顾控制、隐私与长期安全的高端财富规划策略方面的承诺。通过强化其基金会制度，RAK ICC正巩固其在阿联酋的地位，成为寻求安全、灵活且符合国际合规标准的财富保全与跨代规划解决方案的可信赖合作伙伴。关于RAK ICC阿勒哈伊马国际公司注册中心（Ras Al Khaimah International Corporate Centre，简称RAK ICC）是一家总部位于阿联酋阿勒哈伊马的公司注册机构。该机构提供国际商业公司及基金会架构，通常用于私人及商业结构设计、资产整合以及继承规划。截至目前，RAK ICC已注册成立数千家国际公司，并为数十亿迪拉姆的结构化资产提供支持。其服务对象包括高净值人士、企业家及寻求灵活、安全的长期商业与财富管理方案的企业。媒体咨询请联系我们:Phone: +971 7 207 7177Email: info@rakicc.comWebsite: https://www.rakicc.com/contact-us/来源: RAK ICC Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

东京, 2025年8月14日 - (亚太商讯 via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd.（总公司：东京都中央区、执行总裁：田中 浩一朗）决定与株式会社JEPLAN（总公司：神奈川县川崎市、代表取缔役 社长兼执行总裁：高尾 正树、以下简称“JEPLAN”） 开展业务合作，以减少TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.在贵金属回收工艺中的CO₂排放，并推进有机物的资源化再利用。本次合作由长期致力于在贵金属领域推动循环经济（Circular Economy）的TANAKA、以及在塑料领域持续精进技术的的JEPLAN携手推动，旨在实现脱碳化和循环型社会的目标。TANAKA迄今为止为实现循环型社会所方面的努力TANAKA自1885年创业以来，作为贵金属行业的领军企业长年致力于稀缺资源贵金属的回收。其中受客户委托回收的工序废弃物中，对于以有机物（塑料）为主要成分、且附着或吸附有贵金属的工序废弃物，一直以来通过烧成工艺去除有机物，并从剩余的灰烬中回收贵金属。尽管这种烧成处理方式能够有效去除环境管制物质，但在去除过程中有机物燃烧所产生的CO₂排放，成为实现脱碳社会的课题。通过与JEPLAN业务合作、革新贵金属回收工艺JEPLAN已建立了针对聚对苯二甲酸乙二醇酯（PET，一种塑料）的创新化学回收技术。为了解决上述CO₂排放量的课题，TANAKA通过与JEPLAN的业务合作，除了传统的采用烧成的贵金属回收工艺以外，还在考虑未来利用化学回收处理的工艺。预期的化学回收处理的对象为注射器、擦拭布等塑料。预计通过该技术，贵金属回收工艺中的CO₂排放量可控制在以往的10%左右。此外，该新工艺不仅可以回收贵金属，也可以实现塑料再生，TANAKA与JEPLAN将充分发挥各自在专业领域的优势，共同为实现脱碳和循环型社会贡献力量。 　株式会社JEPLAN总公司所在地：神奈川县川崎市川崎区扇町12-2成立：2007年1月代表人：代表取缔役 社长兼执行总裁　高尾 正树主要业务内容：PET化学回收技术相关业务（对象：PET塑料瓶、聚酯）等官方 HP：http://www.jeplan.co.jpJEPLAN集团以“循环一切”为使命，致力于实现循环经济。通过使用创新的PET化学回收技术，将废弃PET（PET塑料瓶、聚酯纤维等）分解至分子水平并去除杂质，使其重新生成与石油基材料同等品质的再生材料。通过使用这项创新技术致力于回收再利用，实现有限资源的循环，并为减少CO₂排放量做出贡献。关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20250814_CN.pdf  Copyright 2025 亚太商讯 via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - SGX Catalist-listed AsiaMedic Limited (the “Company” and, together with its subsidiaries, the “Group”) announced its unaudited financial results for the six months ended 30 June 2025 (“1H2025”), delivering 26% year-on-year revenue growth to S$16.6 million, up from S$13.2 million in 1H2024.This performance was led by the Group’s diagnostic imaging business, which contributed over 60% of total revenue, supported by strong demand at its flagship Shaw Centre clinic and contributions from the newly opened Novena imaging centre.Financial Highlights:Revenue up 26% to S$16.6 million, from S$13.2m in 1H2024, driven by strong growth in diagnostic imaging and steady performance in medical wellness.EBITDA attributable to owners of the Company was maintained at S$1.3 million, reflecting consistent contributions from core businesses, even as the new Novena centre incurred ramp-up losses.Net loss attributable to owners of the Company narrows significantly to S$38,603 from S$104,431 in 1H2024.Cash and cash equivalents stood at S$4.9 million, with an additional S$3.6 million in financial assets, reflecting strong underlying liquidity despite investments into Novena centre.Profitability was significantly affected by the new Novena imaging centre as it remains in its ramp-up phase. However, the Group’s financial performance reflects solid execution of its core business strategy amidst expansion.Mr Arifin Kwek (郭致宾), Chief Executive Officer of AsiaMedic Limited, said, “Our performance in the first half of 2025 reflects the continued strength of our diagnostic imaging business. Shaw Centre remained our primary growth engine with sustained patient volumes, while the newly opened Novena Centre, though still ramping up, has already begun contributing. These investments will further position us as a trusted provider of early detection and preventive care in Singapore.Our health screening and medical wellness segment remained stable, underpinned by the government awarded Grow Well SG programme and steady corporate wellness demand. While the opening of Novena has added to our cost, these are deliberate investments in capacity, technology, and skilled professionals in a key medical geographical location in Singapore, that position us for long term growth.We will continue to build on this foundation, focusing on scaling our imaging and health screening businesses while ensuring we deliver high quality, patient-centred care. With expanded capacity and prudent cost management, AsiaMedic is well placed to capture growth opportunities in Singapore’s healthcare sector.”As Singapore continues to position itself as a regional healthcare hub, AsiaMedic is well-placed to meet growing demand for accessible, high-quality diagnostic and preventive healthcare services. With established centres in Orchard and Novena — two of the country’s key medical precincts — the Group is strategically expanding its reach to serve a broader patient base. This geographic presence, supported by ongoing investments in technology, infrastructure, and clinical talent, positions AsiaMedic to play a meaningful role in advancing Singapore’s preventive care and early detection agenda.This media release should be read in conjunction with the financial statements announced on SGXNet.About AsiaMedic LimitedAsiaMedic Limited together with its subsidiaries (“AsiaMedic” or the “Group”) is a leading healthcare provider in Singapore which provides holistic solutions through integrated application of the latest medical technologies to preventand detect early illnesses to achieve positive experiences and clinical outcomes for patients. AsiaMedic is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (SGX-ST).The Group is committed to helping clients through practical and personalised solutions delivered with the highestprofessional standards of service and expertise in a timely, safe and consistent manner.With convenient locations at Orchard and Novena, AsiaMedic is a preferred one-stop centre for:Diagnostic imaging and radiology servicesMedical wellness and health screening servicesPrimary healthcare servicesMedical aesthetic services and productsFor more information, please visit www.asiamedic.com.sgFor media and analysts’ queries, please contact:Waterbrooks ConsultantsWayne KooT: (65) 9338 8166 / (65) 8901 9780E: wayne.koo@waterbrooks.com.sg / query@waterbrooks.com.sgThis announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd. It has not been examinedor approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Ms Pauline Sim (Registered Professional) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 6319 4954. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm.The Food Expo, Beauty & Wellness Expo, Home Delights Expo will be extended and close at 11pm from 15 August to 17 August, allowing public visitors to enjoy shopping in these fairs—with a single ticket. The Food Expo PRO and Hong Kong International Tea Fair will remain open until 6pm today and tomorrow (14 to 15 August) and until 5pm on Saturday (16 August), enabling trade buyers and exhibitors to continue their business discussions.Admission tickets valid for today may be used for entry on any of the remaining fair days.Sessions 2 and 3 of the International Conference of the Modernization of Chinese Medicine afternoon programme will be resumed in a hybrid format.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - FWD Group Holdings Limited (“FWD Group” or “FWD”) today marked its 12th anniversary by announcing 12 charitable grants dedicated to supporting local communities across Asia.Since its founding in 2013, FWD has grown from its beginnings in Hong Kong SAR, Macau SAR, and Thailand to now span 10 markets across Asia, including Cambodia, Indonesia, Japan, Malaysia, the Philippines, Singapore, Vietnam.The 12 grants are focused on supporting non-government organisations (NGOs) with initiatives spanning financial literacy, social entrepreneurship, career readiness, and health and wellbeing in communities.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “Celebrating our 12th anniversary as a newly listed company makes this milestone especially meaningful. The life insurance business is a deeply personal one, with FWD now touching the lives of 30 million people and their families across Asia. With caring as one of our core values at FWD, giving back in tangible and impactful ways to the wider community is a big part of our vision of changing the way people feel about insurance.”Earlier this year, FWD extended its regional partnership with JA (Junior Achievement) Worldwide – a youth-focused charity and Nobel Peace Prize 2025 nominee – to reach 40,000 more students across Asia by the end of 2027 with its award-winning financial literacy programme. In the next phase, the programme aims to integrate new tools to strengthen financial literacy, mental wellness, and resilience – while involving more teachers and families in the process.The 12 NGO grants include:- Cambodia: Partnering with Cambodia Children’s Fund to launch the "Let’s Save Debate," a university-level initiative promoting financial literacy through debate and research.- Hong Kong SAR: Expanding the JA SparktheDream programme with Junior Achievement Hong Kong and introducing the JA SparktheDream Wellness Workshop that blends financial education with social and emotional learning to engage primary school students.Supporting WISE (Women In Sports Empowered Hong Kong Limited) with its programme to empower teenage girls through sports for mental wellbeing and self-confidence.- Indonesia: Supporting InnovateHer Academy 3.0 with KUMPUL.ID to equip female entrepreneurs with business skills, mentorship, and investment readiness skills.Launching a new financial education programme with Prestasi Junior Indonesia on the back of the best practices from the JA SparktheDream programme. The new programme will equip 30 school teachers with the skills and knowledge to deliver engaging and effective financial literacy lessons.- Japan: Partnering with the National Welfare Beauty and Barber Training Association to provide medical wigs and support for cancer patients during Breast Cancer Awareness month.- Malaysia: Launching the Bijak Ibu Jaga Anak & Kewangan (B.I.J.A.K.) programme with GivingHub to provide 200 low-income families with health and financial literacy educational workshops as well as 200 health screenings and consultations.- Philippines: Collaborating with Junior Achievement Philippines on JA Forward Your Success to support graduating college students with financial literacy and career planning.- Singapore: Supporting Club Rainbow (Singapore) in helping children with chronic illnesses and their families by joining Ride & Ralk for Rainbows 2025, along with a visit to Mandai Wildlife Reserve for children and youths with rare genetic and neurological disorders.- Thailand: Sponsoring seven hospitality scholarships via Pimali Foundation for disadvantaged youth, helping them build sustainable careers.Expanding the JA SparktheDream programme with Junior Achievement Thailand by training 30 teachers in financial literacy to deepen their financial management skills and better support students.- Vietnam: Supporting Be A Finnovator with the Startup Vietnam Foundation on a training and debate competition for university students to build financial leadership, critical thinking, and responsible money habits.About FWD GroupFWD Group is a pan-Asian life and health insurance business that serves approximately 30 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 1828. For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2025 - (ACN Newswire via SeaPRwire.com) - As the Black Rainstorm Warning Signal was issued at 7:50am, the opening of Food Expo, and the concurrent Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo, will be postponed. The opening ceremony originally scheduled for 10:30am, is cancelled. The International Conference of the Modernization of Chinese Medicine will be accessible via livestream.The organiser will make appropriate arrangements to ensure the safety of those already at the venue and will closely monitor the weather conditions. The organiser will open the Food Expo, Food Expo PRO, Hong Kong International Tea Fair, Beauty & Wellness Expo and Home Delights Expo two hours after the Black Rainstorm Warning Signal is cancelled.HKTDC Food Expo PROfoodexpopro.hktdc.comHKTDC Hong Kong International Tea Fairhkteafair.hktdc.comHKTDC Food Expohkfoodexpo.hktdc.comHKTDC Beauty & Wellness Expohkbeautyexpo.hktdc.comHKTDC Home Delights Expohomedelights.hktdc.comThe International Conference of the Modernization of Chinese Medicine (ICMCM)icmcm.hktdc.comMedia enquiriesOgilvy Public Relations:Rex Cheuk+852 5618 9908rex.cheuk@ogilvy.comDaisy Leung+852 9275 7704daisy.leung@ogilvy.comLeanne Pok+852 9379 9694leanne.pok@ogilvy.comHKTDC's Communications and Public Affairs DepartmentStanley So+852 2584 4049stanley.hp.so@hktdc.orgSerena Cheung+852 2584 4272serena.hm.cheung@hktdc.orgClayton Lauw+852 2584 4472clayton.y.lauw@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.comAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 亿胜生物科技有限公司（"亿胜生物"或"集团"，股票代码：1061.HK）欣然宣布，集团针对重组抗VEGF眼内注射液EB12-20145P（HLX04-O）的上市注册申请（"BLA"）最近已被中国国家药品监督管理局（"NMPA"）药品审评中心（"CDE"）受理。该产品由集团与上海复宏汉霖生物技术股份有限公司（"复宏汉霖"，股票代码：2696.HK）合作开发，用于治疗湿性年龄相关性黄斑变性（wet age-related macular degeneration, "wet-AMD"）。此注射液EB12-20145P（HLX04-O）在中国患者中开展的III期临床研究（"AURA-1"）已于今年4月成功达到主要研究终点。AURA-1为一项多中心、随机、双盲、阳性对照的非劣效III期临床研究，旨在比较EB12-20145P（HLX04-O）与雷珠单抗玻璃体内注射（IVT）治疗新诊断的wet-AMD患者的有效性和安全性。除其BLA已获NMPA受理申请的AURA-1外，EB12-20145P（HLX04-O）的一项国际多中心III期临床研究（AURA-2）也在欧洲多个国家、澳大利亚、美国和中国顺利开展，AURA-2最后一名患者的最后一次访视已在2025年1月完成。未来，亿胜生物将不懈追求卓越，拥抱创新，持续推动对同类首创(First-in-class)与同类最优(Best-in-class)产品的创新研发，以满足未来更多的临床及商业化需求。关于湿性年龄相关性黄斑变性年龄相关性黄斑变性（AMD）是造成老年人视力损害和不可逆失明的主要原因之一[1]，根据世界卫生组织报告，全球约有3000万AMD患者，每年约有50万人因为AMD而致盲[2]。AMD致盲患者中，以脉络膜新生血管（CNV）为特征的湿性年龄相关性黄斑变性（wet-AMD）比例高达90%。随着老年人口比例的不断上升，wet-AMD已经成为一个日益严重的社会医学问题，存在着巨大的未满足的临床需求[3]。随着眼底治疗方法的突破与发展，抗VEGF药物已成为wet-AMD的一线疗法[4]，贝伐珠单抗玻璃体腔注射治疗wet-AMD的有效性和安全性也已在多项临床研究中得到验证[5-11]。关于亿胜生物（股票代码﹕1061.hk）亿胜生物是一间专注于研发、生产和销售基因工程药物b-bFGF的生物制药企业，拥有包括贝复舒(R)、贝复济(R)、贝复新(R)在内的六种基因工程药物在中国上市销售。此外，公司还拥有包含一系列不含防腐剂单剂量滴眼液和适丽顺(R)卵磷脂络合碘胶囊等的多元化产品组合，主要应用于眼科及皮肤科处方药领域的创伤修复及疾病治疗。这些产品在公司于中国的44个区域办事处的支持下，在逾14,000家医院进行营销和销售。依托自身在生长因子和抗体技术领域的研发平台，亿胜生物在多个临床阶段拥有强大的项目管线，涵盖广泛的领域和适应症。参考文献[1] 欧阳灵艺, 邢怡桥. 抗VEGF药物在湿性年龄相关性黄斑变性中的应用进展[J]. 国际眼科杂志, 2020(1). [2] Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004 Nov;82(11):844-51. [3] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2): e106-116. [4] Li X R, Liu J P. Recognition of anti-VEGF therapy base on the mechanism of VEGF in wet age-related macular degeneration[J]. Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology, 2012, 30(4):289-292. [5] Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi-centre randomized double masked study. BMJ. 2010 Jun 9;340:c2459. [6] Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908. [7] Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012 Jul;119(7):1399-411. [8] Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar -Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology. 2013 Nov;120(11):2300-9. [9] Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group. A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013 Mar;97(3):266-71.[10] Berg K, Pedersen TR, Sandvik L, Bragadóttir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015 Jan;122(1):146-52. [11] Schauwvlieghe AM, Dijkman G, Hooymans JM, Verbraak FD, Hoyng CB, Dijkgraaf MG, Peto T, Vingerling JR, Schlingemann RO. Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. PLoS One. 2016 May 20;11(5): e0153052. Copyright 2025 亚太商讯 via SeaPRwire.com.

Ottawa, Ontario--(ACN Newswire via SeaPRwire.com - August 13, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company"), a leading Canadian graphite developer advancing high-grade projects in Québec, is pleased to announce the resumption of work on the Environmental and Social Impact Assessment ("ESIA") for its 100%-owned Lac Knife flake graphite project located near Fermont, in the province's prolific iron ore mining district.The Company has formally re-engaged IOS Geosciences Inc. ("IOS"), a leading Québec-based geological consulting firm and former general contractor on the ESIA, to complete a total of sixteen (16) technical reports required for submission to Québec's environmental and natural resource authorities. These reports represent a major step in advancing the Lac Knife project toward permitting and the goal of mine construction.The ESIA program, initially launched in 2020, involves multidisciplinary technical evaluations and environmental baseline work conducted across 2020 and 2021. Finalization was delayed due to funding constraints but is now back on track. Report completion is estimated by early 2026, with submissions planned shortly thereafter to the Québec Ministry of Sustainable Development, Environment, and the Fight Against Climate Change ("MDDELCC"), as well as the Ministry of Natural Resources and Forests ("MRNF").The sixteen (16) technical reports in progress cover critical permitting areas, including:Condemnation and pit wall drillingAcid-generating potential analysisGeotechnical drilling and soil mechanicsSoil geochemistry and chemistry baselineLake-bottom geochemical and surface water quality surveysGroundwater habitat assessment and follow-upCaribou habitat assessment and follow-upGeometallurgical and graphite flake characterizationThese comprehensive studies are essential for satisfying Québec's rigorous environmental and social licensing requirements and underscore Focus Graphite's commitment to environmental stewardship and Indigenous engagement through project development.In parallel, Focus has also authorized IOS proceed with geochemical analysis of over 1,000 split and pulverized drill core samples collected from its 2022 exploration drilling program at the Lac Tétépisca ("Tétépisca") graphite project. The samples, targeting the Southwest MOGC and West Limb geophysical (MAG-EM) conductors, will undergo carbon and sulfur determinations at certified laboratories.Upon receipt of assays, IOS will finalize and submit the corresponding technical reports covering 14,900.5 metres of core drilling from 74 holes to the MRNF. An updated Canadian Institute of Mining, Metallurgy and Petroleum ("CIM") and National Instrument ("NI") 43-101 compliant Mineral Resource Estimate ("MRE") for the Manicouagan-Ouest Graphitic Corridor ("MOGC") graphite deposit is anticipated in Fall 2025, which will further define Tétépisca's development potential alongside Lac Knife."Resuming the ESIA is a pivotal milestone that moves us closer to full permitting and our goal of mine development at Lac Knife," said Dean Hanisch, CEO of Focus Graphite. "With most fieldwork and laboratory studies already complete, we're in a strong position to finalize this critical stage efficiently. At the same time, initiating assay work at Tétépisca to support an upgraded mineral resource estimate reflects our commitment to building value across our entire Québec asset base."The Company also announced the grant of incentive stock options as compensation to its directors, officers, employees, and consultants. Options to purchase up to 4,215,000 Common Shares of the Company have been granted at an exercise price of $0.14 per share. The options expire on 13 August, 2030. Additionally, the Company has granted 1,350,000 restricted stock units ("RSUs") to officers, directors, and consultants of the Company under the terms of the Company's restricted share unit and equity incentive plan (the "RSU and EIP Plan"). Each RSU entitles the holder to acquire one common share of the Company after the vesting period in accordance with the Plan.Qualified PersonsThe technical content disclosed in this news release was reviewed and approved by Réjean Girard, P.Geo. (QC), President of IOS Geosciences Inc., a consultant to the Company, and a qualified person as defined under National Instrument NI-43-101.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tétépisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the completion and submission of the sixteen technical reports required for the Lac Knife Environmental and Social Impact Assessment, the anticipated timeline for ESIA report submission and permitting, the initiation and results of geochemical analyses at the Lac Tétépisca project, the anticipated updated NI 43-101 Mineral Resource Estimate for the Tétépisca deposit, the Company's positioning as a near- and long-term secure supplier of specialty graphite materials, and the potential geopolitical significance of Canadian graphite supply.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262450 Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 备受全球科技界关注的世界人形机器人运动会将于8月14日在北京国家速滑馆正式拉开帷幕，这场持续至8月17日的科技盛宴，将成为展现全球人形机器人技术最高水平的重要窗口。作为全球首个以人形机器人为核心参赛主体的大型综合性赛事，本次运动会设置了极具看点的多元竞赛项目。来自世界各地的超百支顶尖机器人战队，将在跑步、足球、街舞、武术、工厂搬运、酒店服务等项目上进行比拼，全面展示人形机器人在不同领域的应用潜力。这背后不仅是技术的较量，更是对机器人适应复杂环境、完成精细任务能力的全方位检验，每一个项目的背后都凝聚着人工智能、机械工程等多学科的技术突破。一、首程控股多维度深度参与本届运动会中，首程控股扮演了资本推动者、场景验证者与生态运营者的三重角色。依托管理的北京机器人产业发展投资基金及多支产业基金，首程已系统投资布局数十家高成长机器人企业，覆盖从核心零部件到整机集成、从底层算法到场景应用的全产业链。此次亮相的被投企业包括：宇树科技（Unitree Robotics）、银河通用（Galbot）、星海图（Galaxea-AI）、松延动力（Noetix Robotics）、加速进化（Booster Robotics）、自变量机器人（X Square Robot）等，分别在足球、田径、格斗、舞蹈、场景赛等核心项目中担纲主力。二、首程机器人科技体验店打造沉浸式产业橱窗运动会期间，位于国家速滑馆内的首程机器人科技体验店同步开放，集中展示50余家企业近200款产品，涵盖智慧家居、教育、智能穿戴、娱乐休闲等多个场景。观众不仅可以近距离体验人形机器人、智能家电、AI娱乐设备等前沿产品，还可现场购买，实现"发布-测试-销售-服务"的消费闭环。这一举措与首程2025年启动的全球"机器人综合体验店"招募计划一脉相承，将为后续在融石广场等地开设的长期体验店积累场景与运营经验。首程控股董事会主席赵天旸表示，机器人市场规模未来将超越汽车行业，中国必将诞生百亿美元市值的机器人企业。而通过运动会这一"产业橱窗"，首程不仅展示被投企业技术实力，更在真实环境中验证其商业化潜力，加速技术从"实验室走向市场"的进程。三、租赁公司保障赛事落地 为保障赛事前期训练与正式比赛，北京机器人租赁公司集中交付了100台赛事指定设备，包括82台加速进化足球赛本体、10台松延动力田径机器人和8台银河通用场景赛机器人。设备已全部进驻国家速滑馆，重点服务足球赛、田径赛及场景赛的训练需求，并由租赁公司与厂商技术团队联合驻场提供全流程技术支持，实现"即交付、即服务"的产业响应。观赛互动福利为感谢市场长期以来的支持，首程控股将通过抽签选出88位幸运观众亲临现场，共同见证这场全球顶尖科技的竞技舞台。报名注册截止日期：北京时间2025年8月14日上午9:00抽签时间：2025年8月14日下午3点前公布，受邀者将收到邮件或短信通知参与方式1.通过链接填写报名信息：https://www.wjx.cn/vm/mfW64yI.aspx#2.关注"首程控股"官方微信公众号，后台留言「机器人运动会」，根据弹出链接填写报名信息。 Copyright 2025 亚太商讯 via SeaPRwire.com.

康基医疗控股有限公司与Knight Bidco Limited今日联合宣布，拟通过协议安排（"建议交易"）对公司进行私有化。康基医疗控股有限公司私有化要约：每股9.25港元的注销价较股份于截至未受干扰日期（即2025年6月30日）之收盘价溢价约21.7%，较股份于截至未受干扰日期（包括该日）止360个交易日在联交所所报的平均收盘价溢价约47.3%，且超过了2022年以来于联交所录得之最高收盘价。本次私有化拟以协议安排方式实施，要约人及其一致行动人士合共持有公司74.75%之股份；已获得一家机构股东作出的不可撤销承诺，将投票支持该私有化方案。该方案为股东提供明确机会，使其能够于康基医疗控股有限公司之股份持续面临交易价格压力及流动性受限之际，变现其于公司之权益。香港，2025年8月13日 - (亚太商讯 via SeaPRwire.com) - 2025年8月12日，康基医疗控股有限公司（"康基医疗"或"公司"，股份代号：9997.HK）与KNIGHT BIDCO LIMITED"要约人"今日联合宣布，双方拟以协议安排的方式对公司进行私有化，以期公司能够专注于长期战略决策，包括研发长期投入及运营升级。待该方案完成后，公司将成为要约人的全资附属公司，而公司股份于联交所的上市地位将被撤销。要约人由以下成员组成的财团全资持有：钟先生与申屠女士（创始人）、TPG实体、NewQuest V基金及Al-Rayyan Holding。交易理据鉴于股票的交易价格持续承压且流动性长期不足，公司从股票市场筹集资金的能力受到严重限制。除此之外，本公司为维持上市地位须承担行政、合规及其他与上市相关之成本及开支，故维持上市地位之裨益有限。由于国内市场竞争加剧及持续之监管不确定性，为实现可持续增长，公司的长期策略需进行重大投资，此举可能对短期财务表现造成压力。预计需将额外资源分配至以下领域：销售与市场推广、研发及商业化投资，以及中国境外之市场扩张。鉴于维持上市地位的裨益有限，且涉及相关上市成本，康基医疗继续维持上市地位之必要性已显著降低。此外，该方案的实施将缓解公司短期财务表现所受压力，从而更专注于战略目标的推进。公司预期需要配置更多资源，以保障其未来可持续发展。此外，该方案为少数股东提供具吸引力的机会，使其能在市场波动、行业及宏观不确定性，以及股份流动性有限之情况下，实现可观回报。KNIGHT BIDCO LIMITED提出的私有化方案为康基医疗及其股东提供了及时有效的解决方案，提议将康基医疗私有化的方案将：(a) 降低康基医疗的行政、合规及其他上市相关成本；(b) 缓解康基医疗面临的短期业绩指标压力，使康基医疗能够专注于长远战略决策（例如可能导致短期亏损的长期研发投入及运营升级）；以及(c) 为现有股东提供明确保障，使其能以显著高于未受干扰股价的溢价，实现于康基医疗的权益变现。综上所述，要约方认为私有化交易能为全体股东提供即时且最具吸引力价值的战略选择，同时可规避不确定市场环境带来的风险。交易方案概述本次私有化方案设定的股份注销价格为每股9.25港元，按股权价值计算对公司估值约为14亿美元[1]。要约方已明确表示，注销价格为最终定价且后续不会上调。该注销价格体现以下考量：较股份于未受干扰日期（即2025年6月30日）在联交所所报收盘价溢价约21.7%。较股份于截至未受干扰日期（包括该日）止360个交易日在联交所所报的平均收盘价溢价约47.3%。以及截至未受干扰日期（包括该日）止于联交所所报之股份价格的过去52周最低收盘价（5.01港币）溢价约84.6%。此外，在较长的过往期间内，注销价格超过了股份自2022年以来的最高收盘价（8.66港币）。本次注销价格的确定已综合考量下列因素（包括但不限于），股份于联交所的近期及历史交易价格，公司公开披露的财务资讯，及参照近年来香港市场类似私有化交易案例。该方案的实施受限于所有先决条件于2026年1月31日（先决条件最后截止日期）或之前达成，并在2026年4月30日（最后截止日）之前满足条件。公司将委任独立财务顾问（"IFA"）向为方案目的而设立的独立董事委员会（"独立董事委员会"）提供意见，以便就方案向股东作出推荐建议。方案的详情，包括独立董事委员会的最终推荐意见及独立财务顾问的意见函，将载入计划文件，并预期在切实可行的情况下尽快寄发给股东。协议安排会议协议安排会议的具体细节将载于计划文件，该文件预计将于适当时候寄发予股东。本次交易尚需满足《联合公告》所列的多项先决条件及条件，包括但不限于监管批准、股东批准及其他法定合规要求。不可撤销承诺本公司已获得一名机构股东作出的不可撤销承诺，将就该项提案投赞成票。详情请参阅《联合公告》。康基医疗已于2025年7月18日上午9时正起于联交所暂停买卖，以待刊发本公告。公司已向联交所申请股份自2025年8月13日上午9点起恢复买卖。摩根大通担任要约方独家财务顾问。关于康基医疗控股有限公司康基医疗控股有限公司创立于2004年，总部位于中国浙江省杭州市，于2020年6月在香港联合交易所主板上市，股票代码9997.HK。公司专注于设计、开发、生产和销售微创外科手术器械及配套耗材（"MISIA"），秉持着"为医生提供优质产品和服务，致力于人类健康事业"为使命，通过丰富的产品组合为妇产科、普外科、泌尿外科和胸外科等临床科室的微创外科手术提供一站式解决方案，并致力于发展为一个立足中国，辐射全球的国际化微创外科手术器械及配套耗材平台。关于Knight Bidco Limited要约人、MidCo 及TopCo均为于开曼群岛新注册成立的有限公司及仅为实施该建议而成立的投资控股公司。于公告日期，要约人由MidCo全资拥有，而MidCo由TopCo全资拥有。于本公告日期，TopCo由财团成员持有，其中Fortune Spring ZM、Fortune Spring YG、TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding分别持有约25.53%、约14.47%、约24.38%、约5.01%、约5.69%、约4.56%及约20.36%。于本公告日期，除《联合公告》中"公司的股权架构"一节所披露外，TPG Asia VII、Keyhole、Knight Success、NewQuest V及Al-Rayyan Holding均非股东。康基医疗现由钟鸣先生及其配偶申屠女士共同控制，二人合计持有康基医疗52.98%股份。待私有化完成后，钟氏夫妇将通过Fortune Spring ZM与Fortune Spring YG继续持有要约方最终控股公司（TopCo）40.00%股权，并保持第一大股东地位。更多细节详见《联合公告》。各创始人实体均为在英属维尔京群岛注册成立的商业公司。Knight Success为一家于新加坡新注册成立的有限公司且为一家投资公司。Keyhole为一家于开曼群岛注册成立之获豁免有限公司及投资控股公司。TPG Asia VII为一家于新加坡注册成立的有限公司。Knight Success及Keyhole均由TPG Asia VII全资拥有或控制，而后者由TPG Asia GenPar VII Advisors, Inc.控制，并最终由纳斯达克上市的特拉华州公司TPG Inc.控制。TPG是一家全球领先的另类资产管理公司，成立于1992年，截至2025年6月30日年管理的资产超过2,690亿美元。多年来，TPG一直致力于投资变革、增长与创新，旨在为投资者构建多元化的产品与策略，同时借由贯彻纪律及卓越的营运管理，提升投资策略与投资组合的整体表现。NewQuest V为一家于新加坡注册成立的有限公司及投资控股公司。NewQuest V由NewQuest Asia Fund V, L.P.全资拥有，而后者由NewQuest Asia Fund V GP Ltd.控制，并最终由纳斯达克上市的特拉华州公司TPG Inc.控制。NewQuest成立于2011年，是亚洲领先的二级私募股权平台之一，拥有亚洲最有经验的二级团队，分布于五个办事处。自成立以来，NewQuest一直专注于与普通合伙人合作，创建定制的解决方案，以满足私募资产持有人及其利益相关者的流动性和其他战略需求。从2018年建立的战略合作伙伴关系开始，NewQuest2022年1月成为TPG的全资附属公司。Al-Rayyan Holding为一家根据卡塔尔金融中心管理局的规定于2012年在卡塔尔成立的有限责任公司，且为卡塔尔主权财富基金卡塔尔投资局全资拥有的间接附属公司。成立于2005年的卡塔尔投资局旨在投资和管理国家储备基金。卡塔尔投资局为全球最大、最活跃的主权财富基金之一。卡塔尔投资局投资于广泛的资产类别及地区，并与世界各地的领先机构合作，建立具有长期前景的全球化及多元化投资组合。于本公告日期，Al-Rayyan Holding及其一致行方（与Al-Rayyan Holding 单独或被视为与该财团一致行事的各方除外）均不持有任何股份。如有垂询，敬请联系：康基医疗控股有限公司要约人传媒联络：皓天财经集团有限公司Angie Li & Jason Lai电话：(+852) 6150 8598 / (+852) 9798 0715电邮：po@wsfg.hk传媒联络: 博然思维Kay Lau电话：+852 6021 7009Tong Li电话：+86 134 8872 6729电邮：TeamKnight@brunswickgroup.com[1] 以每股9.25港币的注销价格、1,207,994,000股流通股，以及7.85的美元兑港币汇率计算免责声明：本新闻稿中使用的所有未另行定义的大写术语，其含义均以2025年8月12日发布的《联合公告》中的释义为准。本新闻稿须与《联合公告》全文一并阅读，公告副本可在以下链接查阅。https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201339_c.pdf Copyright 2025 亚太商讯 via SeaPRwire.com.

SINGAPORE, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Artificial intelligence has many uses in daily life. From personalized shopping suggestions to voice assistants and real-time fraud detection, AI is working behind the scenes to make experiences smoother and more seamless. Behind every smart AI feature is a process that involves two distinct stages: AI training and AI inference. While they're both essential to building intelligent systems, they serve very different purposes and have unique requirements. Let's break down the differences between training and inference.What is AI training?AI training is the process of feeding an AI model large volumes of data, so it learns to recognize patterns and generate the required output.Training generally requires large volumes of labeled or unlabeled data, each of which may facilitate different forms of training.Labeled data: Some projects require a model to make decisions or generate output based on established patterns or correlations. Here, it makes sense to train the model on labeled data using supervised learning techniques.Unlabeled data: Training models on unlabeled data lets them detect new patterns and build an understanding of the relationships between inputs and outputs. This is called unsupervised learning.Think of AI training like teaching a student using flashcards, quizzes, and feedback. During training, the model constantly adjusts internal parameters (often millions or billions of them) to minimize errors and improve accuracy. This phase is computationally intensive and requires specialized hardware like GPUs or TPUs to process large datasets efficiently.For example, training an AI model to recognize objects in images might involve showing it millions of labeled photos of cats, cars, and coffee mugs until it can correctly identify these objects on its own.What is AI inference?Once a model has been trained, it's ready to perform tasks. AI inference is the process of using a trained model to make predictions or decisions on new, unseen data.Inference is typically faster and more lightweight than training. It's used in real-time applications like chatbots, recommendation engines, voice recognition, and edge devices like smartphones or smart cameras. Inference is the test of training. If the output or predictions from your model are inaccurate, you may need to go back to testing.Going back to the earlier example, inference is what happens when you upload a photo to your phone and the AI instantly recognizes your pet as a "cat." The model has been trained to recognize cat images; it just applies what it already knows.Where AI training and inference differThough both stages are part of the same AI lifecycle, they differ significantly in purpose, speed, and system requirements. Here's a closer look at the key differences:ObjectiveTraining aims to teach the AI model by exposing it to data and helping it learn relationships, rules, and patterns.Inference uses the trained model to generate output (such as predictions, classifications, or decisions) based on new data.Time takenTraining can take hours, days, or even weeks, depending on the size of the model and the complexity of the data. It's a resource-heavy, iterative process.Inference happens much faster, often in real time or near real time.Infrastructure needsTraining requires high-performance computing resources such as powerful GPUs or TPUs, and large memory bandwidth. Most training happens in cloud environments or specialized data centers.Inference can often run on lower-powered devices, including edge hardware like mobile phones or IoT devices. Dedicated inference servers or GPU instances may still be needed in some cases.AI training and inference work hand in hand, but they have different goals, requirements, and challenges. Training is about teaching the model, and inference is about putting it to work. Organizations planning AI projects must consider both phases when budgeting, selecting hardware, and choosing infrastructure.CONTACT:Sonakshi MurzeManagersonakshi.murze@iquanti.comSOURCE: OneMain Financial Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - The highly anticipated World Humanoid Robot Games will officially open on 14 August at the Beijing National Speed Skating Oval and run through 17 August. This four-day technological extravaganza will serve as a premier showcase for the world’s most advanced humanoid robot technologies.As the world’s first large-scale comprehensive competition featuring humanoid robots as the main participants, the Games will include diverse and highly anticipated events such as running, football, street dance, martial arts, factory logistics, and hotel services. Over 100 top-tier robotics teams from around the globe will compete, fully demonstrating the application potential of humanoid robots across multiple domains. Beyond a contest of technology, the Games will be a comprehensive test of robots’ adaptability to complex environments and their ability to perform precision tasks, representing breakthroughs across AI, mechanical engineering, and other disciplines.1. Multi-Dimensional Involvement of Shoucheng HoldingsIn this year’s Games, Shoucheng Holdings acts as a capital enabler, scenario validator, and ecosystem operator. Through the management of the Beijing Robotics Industry Development Investment Fund and other industrial funds, Shoucheng has systematically invested in dozens of high-growth robotics companies, covering the entire value chain from core components to system integration, from fundamental algorithms to scenario applications. Its portfolio companies participating in the Games include Unitree Robotics, Galbot, Galaxea-AI, Noetix Robotics, Booster Robotics, and X Square Robot, each taking a leading role in core events such as football, track-and-field, combat, dance, and scenario competitions.2. Shoucheng Robotics Technology Experience Store – An Immersive Industry ShowcaseDuring the Games, the Shoucheng Robotics Technology Experience Store located inside the National Speed Skating Oval will be open to the public, displaying nearly 200 products from over 50 companies. These exhibits span smart home, education, wearable tech, and entertainment sectors. Visitors can experience cutting-edge products such as humanoid robots, smart appliances, and AI entertainment devices up close, and make on-site purchases – completing a “launch–test–sales–service” consumer loop. This initiative aligns with Shoucheng’s global “Robotics Comprehensive Experience Store” recruitment program launched in 2025, and will provide valuable operational insights for permanent experience stores planned at locations such as Rongshi Plaza.Chairman Zhao Tianyang stated that the robotics market will eventually surpass the automotive industry in scale, and that China will see the emergence of robotics companies valued at tens of billions of US dollars. Through the Games as an “industry showcase”, Shoucheng is not only presenting the technological strengths of its portfolio companies, but also validating their commercial potential in real-world environments – accelerating the journey from “lab to market.”3. Leasing Company Ensures Event DeliveryTo support training and official competitions, Beijing Robotics Leasing Company has delivered 100 designated competition robots, including 82 Booster Robotics football units, 10 Noetix Robotics track-and-field robots, and 8 Galaxea-AI robots for scenario events. All equipment has been deployed at the National Speed Skating Oval, serving training needs for football, track-and-field, and scenario competitions. The leasing company, together with manufacturer technical teams, has established an on-site service team to provide end-to-end technical support, achieving “immediate delivery, immediate service” responsiveness.Spectator EngagementTo thank its long-term supporters, Shoucheng Holdings will draw 88 lucky spectators to attend the Games in person and witness this world-class robotics competition.- Registration deadline: 14 August 2025, 9:00 a.m. (Beijing time)- Draw announcement: Before 3:00 p.m. on 14 August 2025 (Beijing time), with invitations sent via email or SMSParticipation methods:1.Fill out the registration form via: https://www.wjx.cn/vm/mfW64yI.aspx#2.Follow the official WeChat account 'Shoucheng Holdings', leave the message 'Robot Games', and complete the form via the link provided. Copyright 2025 ACN Newswire via SeaPRwire.com.

Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical Holdings Limited by way of a scheme of arrangement (the “Proposal”).Proposed privatisation of Kangji Medical Holdings LimitedThe Cancellation Price of HK$9.25 per share represents a 21.7% premium over the closing price on 30 June, 2025, being the Undisturbed Date, a 47.3% premium over the 360-trading day average closing price up to and including the Undisturbed Date, and exceeds the highest closing price as quoted on the Stock Exchange since 2022The proposed privatisation will be effected by way of a scheme of arrangement; the Offeror Concert Parties collectively hold 74.75% shares in the Company; an Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the ProposalThe Proposal presents shareholders with certainty over their ability to monetise their interests in Kangji Medical Holdings Limited, following a period of sustained pressure on trading prices and limited liquidityHONG KONG, Aug 13, 2025 - (ACN Newswire via SeaPRwire.com) - Aug 12 2025, Kangji Medical Holdings Limited (“Kangji Medical” or the “Company”, Stock Code: 9997.HK) and Knight Bidco Limited (the “Offeror”) today jointly announced a privatisation proposal. The parties intend to implement the privatisation of the Company by way of a scheme of arrangement, with a view to enabling the Company to focus on long-term strategic decisions, such as longer-term business investment in R&D and operations enhancements.Upon completion of the Proposal, the Company will become a wholly-owned subsidiary of the Offeror, and the listing of the Shares will be withdrawn from the Stock Exchange.The Offeror is owned by a consortium comprising Mr. Zhong and Ms. Shentu (the Founders), the TPG Entities, NewQuest V and Al-Rayyan Holding.  Rationale for the ProposalDue to the long-term underperformance in the trading prices and trading liquidity of the Shares, the ability of the Company to raise funds from the equity market has been significantly limited. In addition, the Company has to incur administrative, compliance and other listing related costs and expenses for maintaining the listing status. Accordingly, there are limited benefits for the Company to maintain its listing status.In light of intensifying competition in domestic market and ongoing regulatory uncertainties, and in order to achieve sustainable growth, the Company's long-term strategy requires significant investment which could create short-term pressure on the Company’s financial performance. It is anticipated that additional resources need to be allocated to areas including sales and marketing, investment in research, development, and commercialisation, and the Company’s market expansion outside of China.Considering this, and the listing-related costs, there are limited benefits for Kangji Medical to maintain its listing status. In addition, the implementation of the Proposal will alleviate pressure on Kangji Medical’s short-term financial performance, which enables better focus on strategic objectives. It is anticipated that additional resources will need to be allocated for its future sustainable growth.Furthermore, the Proposal provides minority shareholders an attractive opportunity to realise compelling returns amid market volatility, industry and macro uncertainties, and the limited liquidity of the Shares.Knight Bidco Limited’s proposal offers a timely solution to Kangji Medical and its shareholders. Its proposal to privatise Kangji Medical will:(a) reduce Kangji Medical’s administrative, compliance and other listing related costs;(b) relieve Kangji Medical from the pressure associated with short-term performance metrics and enable Kangji Medical to focus on long-term strategic decisions (such as longer-term investment in R&D and operations enhancements which might incur short-term losses); and(c) present shareholders with certainty over their ability to monetise their interests in Kangji Medical at an attractive premium to the undisturbed share price.In summary, the Offeror believes that a take-private transaction is the strategic alternative that provides immediate and most compelling value for all shareholders, while also avoiding exposure to uncertain market conditions.Overview of the ProposalThe proposal sets out a Cancellation Price of HK$9.25 per share, valuing the company at approximately US$1.4 billion on an equity value basis.[1]The Offeror has indicated the Cancellation Price is final and will not be increased further.The Cancellation Price reflects:A 21.7% premium over the closing price on the Undisturbed Date (being 30 June, 2025).A 47.3% premium over the closing price of 360-trading day average price up to and including the Undisturbed Date.An 84.6% premium over the 52-week closing low (HK$5.01) up to and including the Undisturbed Date.A Cancellation Price above the highest closing price as quoted on the Stock Exchange since 2022 (HK$8.66).The Cancellation Price has taken into account, among other things, the recent and historical prices of the Shares traded on the Stock Exchange, publicly available financial information of the Company and with reference to other similar privatisation transactions in Hong Kong in recent years.The Proposal is subject to satisfaction of the Pre-Conditions by the Pre-Condition Long Stop Date (being 31 January, 2026) and the Conditions by the Long Stop Date (being 30 April, 2026). The Company will appoint an independent financial adviser (the “IFA”) to advise the committee of directors who are considered independent for the purposes of the Proposal (the “Independent Directors”) for the purposes of making a recommendation to shareholders in connection with the Proposal. Details of the Proposal including the Independent Directors’ final recommendation on the Proposal and the IFA’s advice will be included in the Scheme Document, expected to be dispatched to shareholders in due course.Scheme MeetingDetails of the Scheme Meeting to be convened will be contained in the Scheme Document which is expected to be dispatched to shareholders in due course.There are several pre-conditions and conditions as set out in the Joint Announcement, including regulatory approvals, shareholders approval and compliance with other legislative requirements.Irrevocable UndertakingAn Irrevocable Undertaking has been received from one institutional shareholder to vote in favour of the Proposal. Further details are available in the Joint Announcement.Trading in the Shares of the Company has been suspended on the Stock Exchange since 9:00 a.m. on 18 July, 2025, pending the release of this Announcement. The Company has applied to the Stock Exchange for the resumption of trading of Shares with effect from 9 a.m. on August 13, 2025.J.P. Morgan acted as the exclusive financial advisor to the Offeror.Kangji Medical Holdings LimitedKangji Medical is a medical device group founded in 2004 with headquarters at Hangzhou, Zhejiang Province, China. It was listed at the mainboard of the Stock Exchange of Hong Kong in June 2020 (Stock Code: 9997.HK). The Company specializes in the design, development, manufacture and sale of minimally invasive surgery instruments and accessories (“MISIA”). It strives for the mission of “providing physicians with high-quality products and services, and dedicating to improve people’s health”. The Company offers a comprehensive product portfolio to provide physicians and hospitals one-stop and tailored surgical solutions primarily for four major surgical specialties, including obstetrics and gynecology, general surgery, urology, and thoracic surgery. It is also committed to developing an internationally recognized minimally invasive surgery instruments and accessories platform with global coverage.About Knight Bidco LimitedEach of the Offeror, MidCo and TopCo is a newly incorporated company in the Cayman Islands with limited liability and an investment holding company set up solely for the purposes of implementing the Proposal. As at the date of the announcement, the Offeror is wholly owned by MidCo, which in turn is wholly owned by TopCo. As at the date of this announcement, TopCo is held by the Consortium Members, as to approximately 25.53% by Fortune Spring ZM, approximately 14.47% by Fortune Spring YG, approximately 24.38% by TPG Asia VII, approximately 5.01% by Keyhole, approximately 5.69% by Knight Success, approximately 4.56% by NewQuest V and approximately 20.36% by Al-Rayyan Holding. As at the date of this announcement, save as disclosed in the section headed “Shareholding Structure of the Company” in the Joint Announcement, none of TPG Asia VII, Keyhole, Knight Success, NewQuest V and Al-Rayyan Holding is a Shareholder.Kangji Medical is controlled by Mr. Zhong and his spouse Ms. Shentu who together hold 52.98% of the shares in Kangji Medical. Following the privatisation of Kangji Medical, Mr. Zhong and Ms. Shentu will remain the largest shareholders in the ultimate parent company of the Offeror, holding 40.00% of the shares in TopCo via Fortune Spring ZM and Fortune Spring YG. Further details are available in the Joint Announcement.Each of the Founder Entities is a business company incorporated in the British Virgin Islands.Knight Success is a newly incorporated company in Singapore with limited liability and an investment holding company. Keyhole is an exempted company incorporated in the Cayman Islands with limited liability and an investment holding company. TPG Asia VII is a company incorporated in Singapore with limited liability. Each of Knight Success and Keyhole is either wholly owned or controlled by TPG Asia VII, which is in turn controlled by TPG Asia GenPar VII Advisors, Inc. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).TPG is a leading global alternative asset management firm founded in 1992 with more than US$269 billion of assets under management as of 30 June 2025. For many years, TPG has been investing in transformation, growth, and innovation and aims to build dynamic products and strategies for its investors while also instituting discipline and operational excellence across its investment strategies and performance of its portfolios.NewQuest V is a company incorporated in Singapore with limited liability and an investment holding company. NewQuest V is wholly owned by NewQuest Asia Fund V, L.P., which is in turn controlled by NewQuest Asia Fund V GP Ltd. and ultimately controlled by TPG Inc., a publicly traded Delaware corporation (NASDAQ).Established in 2011, NewQuest is one of Asia’s leading secondary private equity platforms with the most experienced secondary team in Asia across five offices. Since its founding, NewQuest has focused on working with GPs to create bespoke, tailored solutions to meet liquidity and other strategic needs of private asset owners and their stakeholders. Starting from a strategic partnership forged in 2018, NewQuest became wholly owned by TPG in January 2022.Al-Rayyan Holding is a limited liability company established in 2012 under the regulations of the Qatar Financial Centre Authority in the State of Qatar, and is a 100%-owned indirect subsidiary of QIA, the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term outlook. As at the date of this announcement, Al-Rayyan Holding and its concert parties (other than those who are, or deemed to be, acting in concert with Al-Rayyan Holding solely in connection with the Consortium) are not interested in any Shares.For enquiries, please contact:Kangji Medical Holdings LimitedOfferorMedia contact: Wonderful Sky Financial Group LimitedAngie Li & Jason LaiTel: +852 6150 8598 / +852 9798 0715Email: po@wsfg.hkMedia contact: Brunswick GroupKatelin Stevenson & Tong Li+852 9875 3351 / +86 134 8872 6729TeamKnight@brunswickgroup.com[1] Based on  HK$9.25 Cancellation Price per share, 1,207,994,000 shares outstanding, and USD/HKD of 7.85All capitalized terms which are used in this press release but not otherwise defined herein shall have the meanings ascribed to them in the Joint Announcement dated 12 August, 2025. This press release should be read in conjunction with the Joint Announcement, a copy of which is available on https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0812/2025081201338.pdf. Copyright 2025 ACN Newswire via SeaPRwire.com.

香港，2025年8月12日 - (亚太商讯 via SeaPRwire.com) - 五矿资源有限公司（「MMG」；股份代号：1208）今日发布二零二五年中期业绩，公司除税后净利润达566.3百万美元，较二零二四年上半年的除税后净利润79.5百万美元增长逾600%。这一强劲利润提升主要得益于旗下三座铜矿的铜产量均有所增长，铜、金、银、锌的市场价格上扬，以及Las Bambas因铜产量提升而实现单位成本下降。MMG行政总裁赵晶表示："今年上半年，MMG的业务实现了卓越的经营和财务表现。此成果充分展现出公司资产组合的优势、团队的卓越能力以及对战略规划的坚定执行力。"值得关注的是，二零二五年上半年，MMG的安全绩效有所改善，每百万工作小时可记录总工伤事故频率（TRIF）为1.81，低于二零二四年全年的2.06。二零二五年上半年具有能量交换的重大事件频率（SEEEF）为每百万工作小时0.78，与二零二四年持平。运营方面，公司旗下三座铜矿山的铜销量与产量均显著提升，其中Las Bambas表现强劲，Khoemacau和Kinsevere亦处于爬坡阶段。澳大利亚两座矿山虽面临天气影响、设备可靠性以及采矿顺序导致的品位下降等挑战，锌产量仍保持稳定。要点：上半年的EBITDA及EBIT均创下历史新高，其中EBITDA达1,539.9百万美元，较二零二四年上半年增长98%，而EBIT总计1,058.8百万美元，较去年同期增长240%。除税后净利润达566.3百万美元，包括本公司权益持有人应占利润340.0百万美元。经营活动现金流净额较二零二四年上半年增长130%，总额达1,185.0百万美元。这主要受铜销售量增加及商品价格上涨推动。资产负债持续改善，自Las Bambas收购以来，债务净额及杠杆率均创下历史新低。其中，债务净额自二零二四年底以来减少903.3百万美元，主要得益于强劲的运营现金流及提前偿还Khoemacau合营公司集团500百万美元的贷款。二零二五年上半年，杠杆率从41%下降至33%。二零二五年上半年，应付铜销售总量达237,651吨，创二零一八年以来历史新高。Las Bambas二零二五年上半年铜精矿含铜的产量达210,637吨，较二零二四年同期增长67%。EBITDA创下历史新高，达1,310.5百万美元，较二零二四年上半年增长122%。赵晶补充道："MMG的资产负债表达至十年来最稳健水平--受惠于盈利提升和现金流创造带动的债务削减。我们跻身全球十大铜生产商的目标触手可及，透过卓越的运营表现、审慎的资本分配，以及对负责任采矿的持续承诺，我们已为实现这一目标奠定良好基础。"二零二五年的生产指引维持不变，铜总产量最高可达522,000吨，锌产量最高可达240,000吨。如果运营环境稳定且无外部干扰，Las Bambas今年有望实现高达400,000吨的铜产量。MMG正致力达成成本目标，Las Bambas和Rosebery已下调C1成本区间，以反映副产品收益改善及强劲的市场条件。本公司正努力完成近期对巴西镍业的收购，并对公司的长期资产组合及增长前景充满信心。MMG将持续推动运营所在社区的发展，促进当地经济与就业，并为全球可持续未来供应所需的关键矿物。点击查看完整的中期业绩报告，观看行政总裁致辞视频以及下载公司图片。关于MMGMMG成立于二零零九年，其愿景是为低碳未来打造国际领先的矿业公司。公司总部位于澳大利亚墨尔本和中国北京，并在香港联合交易所上市（联交所：1208）。MMG的资产组合涵盖铜、锌和钴的生产，并即将拓展至镍领域。这些金属资源对全球脱碳和电气化目标的实现至关重要。目前，公司的运营业务分布澳大利亚、博茨瓦纳、刚果民主共和国及拉丁美洲。更多信息请点击此处。 Copyright 2025 亚太商讯 via SeaPRwire.com.

俄亥俄州西湖, 2025年8月12日 - (亚太商讯 via SeaPRwire.com) - 全球领先的高性能聚合物解决方案配方、研发和制造企业GEON®高性能解决方案公司今日宣布，其位于美国、加拿大、墨西哥和中国的分支机构已获得Great Place To Work®（GPTW，“最佳职场”）认证。自2021年与GPTW合作以来，GEON一直秉持着文化与可持续发展的愿景，力争每年都获得这一殊荣。通过 GPTW 认证GEON获美国、加拿大、墨西哥和中国“最佳职场”认证。GPTW要求员工对自身体验、职场文化以及领导行为进行量化评估和基准比较，这些因素已被证明能够带来市场领先的营收、员工留任率的提升以及创新能力的增强。“我们非常高兴能在公司运营的四个国家连续两年获得‘最佳职场’认可。‘最佳职场’的评选是与全球顶尖雇主进行比较的，这证明了我们在追求卓越企业文化的道路上正走在正确的方向上。”GEON首席执行官特蕾西·加里森（Tracy Garrison）表示，“我们相信，市场上的领导者也必须是职场上的领导者。为此，我们在全球各地的运营中都致力于营造积极的工作文化，同时努力在仍需提升的领域不断进步。”GEON获得了79%的员工敬业度评分，比典型公司高出20%以上。在美国、加拿大和中国，GEON的评分较去年有所提升，在墨西哥则保持稳定。美国的调查涵盖了GEON的所有员工，包括 GEON于2025年1月收购的Foster, LLC 的员工。根据 Great Place To Work research 的研究，在获得“最佳职场”认证的企业中，求职者找到优秀上司的可能性高出 4.5 倍。此外，在通过认证的企业工作，员工期待上班的可能性高出 93%，并且获得公平薪酬和公平晋升机会的可能性是普通企业的两倍。“正如数据所示，获得 GPTW 认证不仅反映了我们的企业文化，还直接影响了我们留住那些每天都期待来上班的优秀员工的能力。”GEON 首席人力资源官杰罗姆·贝格里（Jerome Beguerie）表示，“这对我们的客户以及他们与我们合作的体验都有直接影响。”关于 GEON 高性能解决方案GEON® 高性能解决方案是聚合物混配解决方案领域的领先创新者，服务于包括建筑与基础设施、消费品、工业、交通运输以及电力与通信等在内的广泛市场。通过收购 Foster, LLC，GEON 进一步增强了在高速增长的医疗保健和医疗器械行业的参与度，并在高度适应性的乙烯基、聚烯烃和工程树脂技术组合基础上，拓展了全方位合同制造业务。GEON 在全球拥有约 1,200 名员工和 15 家世界一流的制造工厂，总部位于俄亥俄州西湖市。了解更多信息，请访问 http://www.geon.com 。GEON 是 SK Capital Partners 投资组合中的一家公司。关于 SK CapitalSK Capital 是一家具有变革力的私募投资公司，专注于特种材料、配料以及生命科学领域。公司致力于打造具有韧性、可持续性和增长潜力的企业，从而创造可观的长期价值。SK Capital 力求利用其在行业、运营和投资方面的经验，寻找机会将企业转型为具有更高绩效、更优战略定位、更强增长与盈利能力且运营风险更低的组织。截至 2024 年 12 月 31 日，SK Capital 管理的资产总额约为 100 亿美元。更多信息请访问 http://www.skcapitalpartners.com 。联系信息Renita AndersonVice President, Marketing & Business Developmentrenita.anderson@geon.com678-772-8953来源: GEON Performance Solutions Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月12日 - (亚太商讯 via SeaPRwire.com) - 中国利郎有限公司（"中国利郎"或"本公司"，及其附属公司，统称"集团"；股份编号：1234）今天公布其截至二零二五年六月三十日止六个月中期业绩。中国利郎主席兼非执行董事王冬星先生说："二零二五年上半年，国际贸易环境更趋严峻复杂。期内，内地消费逐步复苏，但消费者对非必需品的支出仍然谨慎。中国利郎通过差异化品牌矩阵深耕男装市场，通过精准的产品定位与渠道策略，锁定目标客群，推出多款'利郎LILANZ'及'利郎LESS IS MORE'品牌产品，满足消费市场需求。此外，集团积极布局全域营销，加强利郎品牌的知名度，提升线上线下渠道销售效益，以推动整体销售，提升营运效益。"截至二零二五年六月三十日止上半年，集团收入同比增加7.9%至人民币17.3亿元。其中，轻商务及其他系列收入大幅上升31.8%，主要由于轻商务在门店和新零售表现良好的带动。主系列收入轻微下跌0.2%，主要由于集团在山东与重庆推进DTC业务模式带来的一次性收入扣减所致。毛利率为50.2%，同比上升0.2个百分点，主要由于直营销售占比上升提高了平均单价所致。期内权益股东应占利润为人民币2.4亿元（二零二四年上半年：人民币2.8亿元），权益股东应占利润率为14.0%（二零二四年上半年：17.5%），每股盈利为人民币20.2分。期内集团保持财政稳健，现金流充足。董事会建议派发中期股息每股11港仙（二零二四年上半年：13港仙）及特别中期股息每股5港仙（二零二四年上半年：5港仙），继续维持稳定的派息比率。集团积极推进战略转型，并落实"多品牌、国际化"发展策略，实现业务持续扩张。"利郎LILANZ"主系列继续巩固在传统男装市场的竞争优势，成功提升品牌知名度和扩大市场份额。主系列于去年完成东北地区及江苏省的分销及代销权回购转制，并于期内向山东全省和重庆市一级分销商回购经营权，以DTC模式转型。针对较年轻消费者的"利郎LESS IS MORE"轻商务系列继续以全直营模式经营。轻商务新增门店主要集中在西南及中南地区。截至二零二五年六月三十日止，主系列门店共2,443家，轻商务门店331家。期内，集团继续致力优化销售渠道，按计划在优质地段开设购物中心店及奥特莱斯店，及通过科技感的视觉设计和年轻化的空间布局，将"简约不简单"的品牌理念具象化呈现，以提升品牌形象及推动销售。于二零二五年六月三十日，购物商场店增加至957家（二零二四年十二月三十一日933家）；奥特莱斯店则增加至121家（二零二四年十二月三十一日：103家），共有2,774家零售店。集团新零售业务完成战略转型，从过往的库存清理渠道升级为主力新品销售平台，于期内收入录得24.6%的显著增长。集团持续深耕天猫、京东、抖音等成熟销售平台的同时，拓展了拼多多、微信视频号、得物等新兴渠道，形成多元化线上销售网络。集团同时利用小红书、微博等社交平台，持续输出高品质内容，强化内容电商布局，从而深化与消费者的情感联结，并扩展新的业务机遇。集团"多品牌、国际化"发展战略方面，万星威"MUNSINGWEAR"上半年完成交易交割，计划于下半年开设首批实体店。而集团在马来西亚组开设首家门店的计划顺利落实，并于五月份试业，实现海外拓展的成功一步。在产品研发及品牌营销方面，集团致力在面料、工艺和技术上取得突破，实现全产业链自主研发，加强品牌的核心竞争优势。期内，集团创新研发的持久白免烫衬衫、拒水羽绒3.0及耐洗POLO衫在抗皱、快干、耐洗等功能上取得多项认可，成功带动销售增长。为进一步深化品牌年轻化战略，集团于期内借助明星影响力、文化IP联动及沉浸式场景营销，触达各线城市及不同年龄层消费者。展望二零二五年下半年，纵然中国消费市场发展仍然存在不同挑战，中国利郎作为行业的领先者，将继续发挥自身优势，因应消费市场变化和科技创新发展，推动变革转型，提升品牌影响力，实现销售及盈利持续增长。集团在下半年将继续深化转型，主系列将持续在东北地区、江苏省、山东省和重庆市发挥DTC模式的经营优势，以实现稳健扩张。同时，集团将根据各市场的具体情况适度扩大规模，进一步提升营运表现。针对全直营模式经营的轻商务系列，集团将着力加强发展基础，维持目前高速发展的势头。集团预期DTC模式于下半年充分释放潜力，为整体销售增长作出贡献。另一方面，集团继续利用销售渠道改革的优势，聚焦省会城市及地级市优质购物中心的核心位置开店，并关闭低效店铺，以提升门店效率；同时亦会审慎布局奥特莱斯店，增加门店数量以加快清理库存。二零二五年全年净开店目标为50至100家门店。为实现线上线下同步发展，集团将致力推进新零售业务发展，继续善用各个平台，以瞄准年轻客户群并加强品牌渗透。透过多维度增加品牌曝光，目标新货品销售占电商销售总金额的比重能提高至80%。同时，集团会通过智慧物流园区的持续升级，进一步优化供应链响应速度，满足消费者需求。集团目标于二零二五年实现新零售业务收入增长20%或以上，整体销售增长目标不少于10%。凭借在国内的坚实基础，集团有信心加速实现"多品牌、国际化"发展策略。万星威"MUNSINGWEAR"作为多品牌策略的重点项目，下半年会继续聚焦产品开发，满足新中产阶级对个性化、功能性及可持续时尚的需求。海外业务方面，集团下半年将在马来西亚开设更多门店，进一步开拓马来西亚的市场，并同时积极部署把业务计划扩大至东南亚其他市场。同时，集团将通过与跨界IP的合作，提升品牌知名度。结合精准的社交媒体行销和会员计划，集团将进一步增强与消费者的互动，提升顾客黏性，提升市场份额。王冬星主席总结说："纵然中国消费市场发展仍然充满挑战，但中国政府实施多项提振消费措施，集团对零售市道审慎乐观。'利郎LILANZ'主系列及'利郎LESS IS MORE'轻商务系列实现创新转型后，各自定位更为清晰，有利集团从产品开发设计、营销推广和销售方面，做到更精准更高效，成为集团长远增长动力。另一方面，作为可持续发展的坚定践行者，集团将ESG理念深度融入企业战略，持续推动绿色创新与社会共赢。集团于期内首次发布独立编制的ESG报告《共创美好生活》，并正式成立ESG管理委员会，将ESG治理纳入战略规划和核心价值观中，展现集团对长期价值的承诺。期内，利郎的MSCI ESG评级升至BB，跻身国内男装行业前列。未来，集团将继续巩固在国内男装行业的领导地位，通过灵活的市场策略和持续创新，实现可持续增长，为股东、员工及客户创造更大价值。"关于中国利郎中国利郎是中国领先的男装企业之一。作为一家综合时装企业，集团设计、采购、生产并以品牌"利郎LILANZ"及"利郎LESS IS MORE"销售优质男士商务及休闲服装。其产品主要于遍布中国31个省、自治区及直辖市的广阔零售及分销网络销售。 Copyright 2025 亚太商讯 via SeaPRwire.com.